This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
LAP07 was a phase 3 randomized treatment trial investigating therapeutic strategies for patients with locally advanced pancreatic cancer that could not be removed by surgery.
| Feature | LAP07 |
|---|---|
| Condition | Pancreatic Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Study period | Start date: 2008-02; Primary completion date: 2013-02 |
2. Clinical Question
Population
Patients with locally advanced pancreatic cancer that cannot be removed by surgery.
Interventions
Gemcitabine hydrochloride, capecitabine, erlotinib hydrochloride, radiation therapy, and laboratory biomarker analysis.
Comparator
The randomized parallel treatment comparisons among the four study arms.
Primary question
The primary statistical question was whether treatment strategies influenced overall survival.
3. Trial Design
Patients were assigned in a randomized study design.
The trial used a parallel design with four arms.
The registry reports no masking.
Overall survival from randomization to death or last known alive date.
Treatment Components
Gemcitabine-Based Strategies
The interventions included gemcitabine hydrochloride with or without capecitabine and/or radiation therapy.
Erlotinib Strategies
The interventions included gemcitabine with or without erlotinib hydrochloride.
4. Endpoints
| Endpoint | Definition |
|---|---|
| Overall survival | Time from the date of the first randomization to the date of patient death due to any cause, or to the last date the patient was known to be alive, assessed up to 8 years after the beginning of the study. |
5. Planned Analysis
The registry identifies overall survival as the primary endpoint. For a randomized oncology trial with an overall survival endpoint, the typical statistical approach is a time-to-event analysis using survival methods that account for patients who are still alive at the last follow-up through censoring.
The registry specifies that an interim analysis was planned when 196 deaths would be observed. No formal statistical analyses were posted to ClinicalTrials.gov.
The analysis of overall survival compares the timing of events between randomized groups rather than simply comparing the proportion of deaths at a single time point.
6. Statistical Methodology
Time-to-event analysis
Overall survival endpoints are commonly analyzed using methods designed for censored survival data. Patients without a recorded death at the analysis cutoff contribute information until their last known follow-up.
Interim analysis
The registry states that an interim analysis was planned after 196 deaths were observed. Interim analyses require prespecified statistical approaches to preserve appropriate control of false-positive findings when data are reviewed before study completion.
7. Statistical Methods Explained
Why is overall survival analyzed as a time-to-event endpoint?
Overall survival includes both whether an event occurred and when it occurred. Survival methods use the available follow-up from all participants, including those who have not yet experienced death.
What does censoring mean in survival analysis?
Censoring occurs when a patient's exact event time is not observed within the study period. The available follow-up information is retained rather than treating the patient as having no event.
Why was randomization important?
Random allocation helps balance known and unknown factors between treatment groups, allowing differences in outcomes to be attributed more reliably to the assigned strategies.
Why does an interim analysis require statistical planning?
Repeatedly examining accumulating data can increase the chance of observing a difference by chance alone. Interim monitoring methods account for this possibility.
Why is the number of events important in survival trials?
The amount of information in survival analysis depends heavily on observed events. The registry identifies 196 deaths as the planned point for an interim analysis.
8. Limitations
- No posted statistical results: ClinicalTrials.gov does not report estimates, confidence intervals, or p-values for the primary endpoint.
- Limited public detail: The registry information available here does not include baseline characteristics, subgroup analyses, safety outcomes by arm, or detailed statistical analysis plans.
- Survival interpretation: Overall survival analyses depend on follow-up duration, censoring patterns, and the prespecified statistical model.
9. Why This Trial Matters Statistically
| Concept | How it appears in LAP07 |
|---|---|
| Randomization | Randomized parallel phase 3 design |
| Multiple arms | Four-arm treatment comparison structure |
| Survival analysis | Primary endpoint based on time from randomization to death |
| Interim analysis | Planned assessment after 196 deaths |
| Censoring | Required for patients alive at last follow-up |